Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 51 articles:
HTML format



Single Articles


    July 2021
  1. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  2. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    


  3. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  4. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available


  5. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available


  6. PLYM A, Penney KL, Kalia S, Kraft P, et al
    Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer.
    J Natl Cancer Inst. 2021 Apr 1. pii: 6207974. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  7. KIBEL AS, Inman BA, Pachynski RK, Vu T, et al
    Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
    J Natl Cancer Inst. 2021 Feb 25. pii: 6149481. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  8. KENSLER KH, Pernar CH, Mahal BA, Nguyen PL, et al
    Racial/ethnic variation in PSA testing and prostate cancer incidence following the 2012 U.S.P.S.T.F. recommendation.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955778. doi: 10.1093.
    PubMed     Abstract available


  9. ETZIONI R, Nyame YA
    Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955775. doi: 10.1093.
    PubMed    


  10. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    


    October 2020
  11. HURWITZ LM, Agalliu I, Albanes D, Barry KH, et al
    Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.
    J Natl Cancer Inst. 2020 Oct 3. pii: 5917632. doi: 10.1093.
    PubMed     Abstract available


  12. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    


    September 2020
  13. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    


    August 2020
  14. DRAGO JZ, Gonen M, Thanarajasingam G, Sacks CA, et al
    Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.
    J Natl Cancer Inst. 2020 Aug 28. pii: 5898636. doi: 10.1093.
    PubMed     Abstract available


  15. DARST BF, Dadaev T, Saunders E, Sheng X, et al
    Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898200. doi: 10.1093.
    PubMed     Abstract available


  16. ROBERTS AW, Eiffert S, Wulff-Burchfield EM, Dusetzina SB, et al
    Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer.
    J Natl Cancer Inst. 2020 Aug 17. pii: 5893484. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  17. LEHRER S, Rheinstein PH
    Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    J Natl Cancer Inst. 2020 Jun 30. pii: 5865274. doi: 10.1093.
    PubMed    


  18. MADAN RA, Antonarakis ES, Drake CG, Fong L, et al
    Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    J Natl Cancer Inst. 2020;112:562-573.
    PubMed     Abstract available


    May 2020
  19. JEMAL A, Culp MB, Ma J, Islami F, et al
    Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    J Natl Cancer Inst. 2020 May 20. pii: 5837113. doi: 10.1093.
    PubMed     Abstract available


    April 2020

  20. Erratum to "Lifetime benefits and harms of PSA-based risk screening for prostate cancer".
    J Natl Cancer Inst. 2020 Apr 23. pii: 5824307. doi: 10.1093.
    PubMed    


  21. GULATI R, Morgan TM, A'mar T, Psutka SP, et al
    Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
    J Natl Cancer Inst. 2020;112:384-390.
    PubMed     Abstract available


    March 2020
  22. JAMASPISHVILI T, Patel PG, Niu Y, Vidotto T, et al
    Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN).
    J Natl Cancer Inst. 2020 Mar 4. pii: 5780290. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  23. HEIJNSDIJK EAM, Gulati R, Tsodikov A, Lange JM, et al
    Lifetime benefits and harms of PSA-based risk screening for prostate cancer.
    J Natl Cancer Inst. 2020 Jan 9. pii: 5698713. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  24. LIAUW SL, Ham SA, Das LC, Rudra S, et al
    Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.
    J Natl Cancer Inst. 2019 Nov 15. pii: 5625912. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  25. MOMOZAWA Y, Iwasaki Y, Hirata M, Liu X, et al
    Germline pathogenic variants in 7,636 Japanese patients with prostate cancer and 12,366 controls.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520440. doi: 10.1093.
    PubMed     Abstract available


  26. JEON J, Olkhov-Mitsel E, Xie H, Yao CQ, et al
    Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5510559. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  27. HUSBY A, Wohlfahrt J, Melbye M
    Vasectomy and prostate cancer risk: a 38-year nationwide cohort study.
    J Natl Cancer Inst. 2019 May 23. pii: 5497506. doi: 10.1093.
    PubMed     Abstract available


  28. MUCCI LA, Wilson KM, Preston MA, Giovannucci EL, et al
    Is vasectomy a cause of prostate cancer?
    J Natl Cancer Inst. 2019 May 23. pii: 5497503. doi: 10.1093.
    PubMed    


  29. KERNS SL, Fachal L, Dorling L, Barnett GC, et al
    Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy.
    J Natl Cancer Inst. 2019 May 16. pii: 5490201. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  30. DONDOSSOLA E, Casarin S, Paindelli C, De-Juan-Pardo EM, et al
    Radium 223-mediated zonal cytotoxicity of prostate cancer in bone.
    J Natl Cancer Inst. 2019 Jan 18. pii: 5292474. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  31. WALSH PC
    RE: Risk of Prostate Cancer in Men Treated With 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Natl Cancer Inst. 2018 Oct 30. pii: 5149366. doi: 10.1093.
    PubMed    


  32. ZHAO SG, Lehrer J, Chang SL, Das R, et al
    The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
    J Natl Cancer Inst. 2018 Oct 13. pii: 5129111. doi: 10.1093.
    PubMed     Abstract available


  33. MADAN RA, Gulley JL
    Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.
    J Natl Cancer Inst. 2018 Oct 13. pii: 5129110. doi: 10.1093.
    PubMed    


  34. YOO YA, Vatapalli R, Lysy B, Mok H, et al
    The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127127. doi: 10.1093.
    PubMed     Abstract available


  35. KARTHAUS WR, Sawyers CL
    Strategies to Identify and Target Cells of Origin in Prostate Cancer.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127123. doi: 10.1093.
    PubMed    


    September 2018
  36. MEIER KE
    Omega-3 Fatty Acids and Prostate Cancer: G Protein-Coupled Receptors to the Rescue.
    J Natl Cancer Inst. 2018 Sep 6. pii: 5091908. doi: 10.1093.
    PubMed    


  37. LIANG P, Henning SM, Guan J, Grogan T, et al
    Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer.
    J Natl Cancer Inst. 2018 Sep 6. pii: 5091911. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  38. YARMOLINSKY J, Bonilla C, Haycock PC, Langdon RJQ, et al
    Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis.
    J Natl Cancer Inst. 2018 May 17. pii: 4996958. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  39. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    March 2018
  40. WALLERSTEDT A, Strom P, Gronberg H, Nordstrom T, et al
    Risk of Prostate Cancer in Men Treated With 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Natl Cancer Inst. 2018 Mar 14. pii: 4935092. doi: 10.1093.
    PubMed     Abstract available


  41. THOMPSON I JR., Goodman P, Tangen C
    Reduced Risk of Prostate Cancer With 5alpha-Reductase Inhibitors.
    J Natl Cancer Inst. 2018 Mar 14. pii: 4935098. doi: 10.1093.
    PubMed    


  42. UNGER JM, Hershman DL, Till C, Tangen CM, et al
    Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst. 2018 Mar 9. pii: 4925555. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  43. COGHILL AE, Engels EA, Schymura MJ, Mahale P, et al
    Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States.
    J Natl Cancer Inst. 2018 Feb 26. pii: 4911376. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  44. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    December 2017
  45. WYATT AW, Annala M, Aggarwal R, Beja K, et al
    Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    October 2017
  46. BROUGHMAN JR, Basak R, Nielsen ME, Reeve BB, et al
    Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.
    J Natl Cancer Inst. 2017 Oct 16. doi: 10.1093.
    PubMed     Abstract available


    August 2017
  47. CONTI DV, Wang K, Sheng X, Bensen JT, et al
    Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    April 2017
  48. BRIOLLAIS L, Ozcelik H, Xu J, Kwiatkowski M, et al
    Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    March 2017
  49. KELLY SP, Graubard BI, Andreotti G, Younes N, et al
    Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2017;109:1-9.
    PubMed     Abstract available


    February 2017
  50. POLLACK A, Kwon D, Walker G, Khor LY, et al
    Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
    J Natl Cancer Inst. 2017;109:1-8.
    PubMed     Abstract available


    January 2017
  51. GAO X, Li LY, Rassler J, Pang J, et al
    Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: